Monte Rosa Therapeutics, Inc. GLUE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s net income?
- Monte Rosa Therapeutics, Inc. (GLUE) reported net income of -$44.5M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s net income changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s net income decreased by 194.9% year-over-year, from $46.89M to -$44.5M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s net income has grown at a -19.5% compound annual growth rate (CAGR), from -$73.96M to -$38.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.